– Grunenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for distributing, promoting and selling MSD’s Women’s Health products in Brazil, Central America, Colombia, Mexico and Peru. The portfolio comprises several Women’s Health products, including ZoelyR, NuvaringR, CerazetteR and LivialR. MSD will continue to commercialize NexplanonR/Implanon NXTR throughout that region.
“This agreement represents a major contribution to Grunenthal’s overall growth. Women’s Health is one of our strategic priorities for Latin America. Therefore, we are delighted that MSD has chosen us to distribute, promote, and sell Women’s Health products that are a perfect complement to our existing offerings in this region. The addition of these products to our portfolio will enable us to establish an even stronger footprint in key markets like Brazil and Mexico and become the 2nd largest Women’s Health company in Latin America,” Gabriel Baertschi, Chief Executive Officer Grunenthal, explains. “We are now at the forefront of supporting women’s health in the region,” he stated.
Further terms of the agreement were not disclosed. Grunenthal will take over the distribution, promotion and sales of a product portfolio with attractive growth prospects across Latin America. The agreement propels Grunenthal to become the 2nd largest Women’s Health company in this region with revenues above € 110 million.
Women’s Health is one of Grunenthal’s strategic priorities in Latin America. In January 2017, Grunenthal introduced its Chilean hormone plant, which is the company’s center of excellence for hormone production. It is the most modern facility of its kind in Latin America and improves access to high quality health products for women across the region.
About Grunenthal
The Grunenthal Group is an entrepreneurial, science-based pharmaceutical company specializeing in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a € 2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.
Grunenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Grunenthal Group worldwide. In 2016, Grunenthal achieved revenues of approx. € 1.4 bn.
More information: http://www.grunenthal.com
Follow us on LinkedIn: “GrunenthalGroup”
For further information, please contact: Štěpan Kračala, Global Head Corporate Communications Tel.: +49-241-569-1335, [email protected]Grunenthal GmbH, 52099 Aachen, Germany
(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)